Abstracts tagged "Disease Activity"

Abstract Number: 567 • 2018 ACR/ARHP Annual Meeting
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Burkhard Moeller¹, Philip Bender², Sigrun Eick², Kim Midwood³, Jan Potempa⁴, Stephan Reichenbach⁵, Anja Schwenzer³, Peter M. Villiger⁶ and Alicia Wong³, ¹Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²School of Dental Medicine, University of Bern, Bern, Switzerland, ³Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, ⁴Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, ⁵Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ⁶University of Bern, Bern, Switzerland
Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we…
Abstract Number: 1097 • 2018 ACR/ARHP Annual Meeting
Spatial-Time Cluster Analysis of SLE Disease Activity
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cluster detection is an essential tool in the public health domain with the goal of detecting anomalous clusters of disease cases. We performed a…
Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Laura C. Coates¹, Philip J. Mease², Frank Behrens³, Ana-Maria Orbai⁴, Alexis Ogdie⁵, Michele Brunori⁶, Lichen Teng⁶, Benoit Guerette⁶ and Josef S. Smolen⁷, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Celgene Corporation, Summit, NJ, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
Abstract Number: 1763 • 2018 ACR/ARHP Annual Meeting
Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis
Catherine E. Najem¹, Jung-Jin Lee², Ceylan Tanes², Cassidy Strange², Elliot Friedman², Antoine G. Sreih¹, Rennie L. Rhee¹, Abdallah Geara³, Hongzhe Li⁴, Kyle Bittinger², James D. Lewis⁵, Gary Wu⁵ and Peter A. Merkel⁴, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, ⁴Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, ⁵Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA
Background/Purpose:To explore the mechanisms by which an altered gut microbiota might predispose to ANCA-associated vasculitis (AAV), a comprehensive metabolic profiling of fecal and plasma bile…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 2625 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Reduces ASDAS Faster and More Stable in Ankylosing Spondylitis Patients: Results from a Real World Prospective Cohort Managed By Smart Phone System
Xiaojian Ji, Jian Zhu, Jianglin Zhang and Feng Huang, Rheumatology, Chinese PLA General Hospital, Beijing, China
Background/Purpose: The Smart-phone Spondyloarthritis Management System (SpAMS) is a mobile health tool, specifically designed to conduct prospective clinical studies on SpA/AS in China, using real-world…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 9L • 2017 ACR/ARHP Annual Meeting
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
Vilija Oke¹, Iva Gunnarsson¹, Jessica M. Dorschner², Agneta Zickert¹, Timothy B. Niewold³ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Colton Center for Autoimmunity, New York University, New York, NY

Background/Purpose: Serum induced IFN gene expression (IFN-score) is considered a golden standard to assess IFN activity in SLE. So far, IFN-scores have not been compared…
Abstract Number: 129 • 2017 ACR/ARHP Annual Meeting
Impact of the Multi-Biomarker Disease Activity Score Results on Whether Rheumatologists Changed Biologic Therapy for RA Patients
Jeffrey R. Curtis¹, Kerri Ford², Lang Chen³, Huifeng Yun³ and Fenglong Xie⁴, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Crescendo Bioscience Inc., South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) score is a validated test used to assess disease activity for patients with rheumatoid arthritis (RA). How it is…
Abstract Number: 681 • 2017 ACR/ARHP Annual Meeting
A Panel of Lupus Biomarkers for the Monitoring of Systemic Lupus Erythematosus: Performance Characteristics in Distinct SLE Cohorts
Joan T. Merrill¹, Thierry Dervieux², Jill P. Buyon³, Rosalind Ramsey-Goldman⁴, Kenneth C. Kalunian⁵, Chaim Putterman⁶, John Conklin², Richard Furie⁷ and Michelle Petri⁸, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Exagen Diagnostics, Inc., Vista, CA, ³Medicine, New York University School of Medicine, New York, NY, ⁴FSM, Northwestern University, Chicago, IL, ⁵Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, ⁶Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ⁷Northwell Health, Great Neck, NY, ⁸Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD
Background/Purpose: Antibody titers to double stranded DNA (anti-dsDNA) and complement C3 and C4 proteins have clinical utility in the routine monitoring of systemic lupus erythematosus…
Abstract Number: 1152 • 2017 ACR/ARHP Annual Meeting
Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease
Seoung Wan Nam¹, SuMan Kang², Hyoungyoung Kim³, Ga-Young Ahn⁴, Min Jung Kim³ and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Diagnosis and accurate measurement of disease activity in adult-onset Still¡¯s disease (AOSD) are still challenging due to its heterogeneous clinical manifestations and the lack…
Abstract Number: 1538 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Early Versus Delayed Anti-TNF-α Treatment in Axial Spondyloarthritis
Herman F Mann¹, Jakub Zavada², Šárka Forejtová³, Lenka Szczukova⁴, Zlatuše Křístková⁴ and Karel Pavelka¹, ¹ATTRA, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, ⁴Institute of Biostatistics and Analyses. Faculty of Medicine, Masaryk University, Brno, Czech Republic
Background/Purpose: Anti-TNF-α agents are the mainstay of pharmacotherapy for patients with axial spondyloarthritis (AxSpA) who failed treatment with NSAIDs. A little is known about the…
Abstract Number: 1820 • 2017 ACR/ARHP Annual Meeting
Sustained Effectiveness after Remission Induction with Methotrexate and Step-Down Glucocorticoids in Patients with Early Rheumatoid Arthritis Following a Treat-to-Target Strategy after 2 Years
Veerle Stouten¹, Johan Joly², Diederik De Cock¹, Sofia Pazmino¹, Kristien Van der Elst^2,3, René Westhovens^1,2 and Patrick Verschueren^1,2, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Remission induction with methotrexate (MTX) and a moderate-dose, step-down scheme of Glucocorticoids (GC), (COBRA Slim strategy), showed equally high remission rates at year 1…
Abstract Number: 2312 • 2017 ACR/ARHP Annual Meeting
Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Quest Diagnostics Nichols Institute, clemente, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].